Toggle main menu visibility
About
Products
Global Health
VISITECT CD4 Advanced Disease
VISITECT CD4
Food Intolerance
Allergy
Resources
News & Events
Investor Relations
Directors
Corporate Information
Share Holder Information
Advisors
RNS Announcements
Corporate Governance
Contact
RNS Announcements
To sign up to receive Investor News as it is released please email
Walbrook PR
24/01/20
Grant of Options
17/01/19
VISITECT CD4 350 Nigeria MOH approval
02/12/19
Interim Results - Year Ended 30 September 2019
02/12/19
Nigerian order for VISITECT CD4
25/11/19
Update on Allergy Test Menu
21/11/19
Investor Briefing
22/10/19
Result of AGM
22/10/19
Trading Update and Notice of Interim Results
15/10/19
Holding(s) in Company
14/10/19
Holding(s) in Company
14/10/19
Holding(s) in Company
11/10/19
Holding(s) in Company
10/10/19
Result of General Meeting
27/09/19
Notice of AGM and posting of annual report
23/09/19
Placing & Subscription and Notice of General Meeting
23/09/19
Final Results – Year Ended 31 March 2019
16/09/19
Update on VISITECT® CD4 Advanced Disease test
10/09/19
Purchase Order for Chinese Food Detective® test
20/08/19
VISITECT CD4 Advanced Disease order
16/08/19
Results, Trading Update & Nigerian CD4 Order
06/06/19
Announcement of Results
05/06/19
Holding(s) in Company
03/06/19
Holding(s) in Company
22/05/19
Subscription to raise c.£635,000
17/04/19
Trading Update
18/03/19
CD4 Advanced Disease CE-Mark
06/03/19
VISITECT CD4 Update
01/03/19
Board Appointment
29/01/19
VISITECT CD4 Advanced Disease Validation
10/12/18
Directorate Change
03/12/18
Interim Results - Six months ended 30 Sep 2018
19/10/18
Holding(s) in Company
10/10/18
Trading Update
27/09/18
Allersys CE Mark
14/09/18
Result of AGM
10/09/18
Holding(s) in Company
06/06/18
FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2018
06/08/18
VISITECT® CD4 Advanced Disease Development Update
18/07/18
VISITECT® CD4 commercialisation update
02/07/18
Notice of Results - RNS
28/06/18
Disposal of Infectious Disease Business
21/05/18
VISITECT CD4 Update
08/05/18
Allersys CE Mark
02/05/18
Closure of Omega Diagnostics GmbH
24/04/18
PDRM Dealing
24/04/18
Holding(s) in Company
23/04/18
Holding(s) in Company
23/04/18
Director/PDMR Shareholding
23/04/18
Holding(s) in Company
23/04/18
Director/PDMR Shareholding
20/04/18
Allersys Distributon Agreement
10/04/18
Strategic Review of Operations and Trading Update
10/04/18
Price Monitoring Extension
12/01/18
Holding(s) in Company
21/12/17
Allersys® CE-Mark
14/12/17
CEO Succession
29/11/17
VISITECT
®
CD4 CE-Mark
01/11/17
Change of Registered Address
23/10/17
T
rading Update and Notice of Interim Results
16/10/17
US Supply Agreement
10/10/17
Holding(s) in Company
05/09/17
Exercise of Options and Total Voting Rights
29/08/17
Result of AGM
18/07/17
Result of General Meeting
17/07/17
Result of Open Offer
06/07/17
Sale and leaseback of the building owned by Omega GmbH
30/06/17
Result of Proposed Fundraising
30/06/17
Proposed Fundraising
30/06/17
Final Results - FY17
25/04/17
Trading Update and Notice of Results
21/04/17
Holding(s) in Company
29/03/17
VISITECT® Malaria CE-Mark and successful Indian FDA inspection
07/03/17
Holding(s) in Company
27/02/17
Holding(s) in Company
22/01/17
Update on discussions with Immunodiagnostic Systems Holdings plc
11/01/17
ISO accreditation for manufacturing facility in Pune, India
24/11/16
Holding(s) in Company
17/10/16
Trading Update and Notice of Interim Results
10/08/16
Result of AGM
02/08/16
R&D Grant Funding
04/07/16
Holding(s) in Company
01/07/16
Holding(s) in Company
27/06/16
Final Results - FY16
09/06/16
Holding(s) in Company
21/04/16
Trading Update and Notice of Results
08/02/16
Holding(s) in Company